The therapeutic effectiveness and safety of indenolol, a vasodilating β-blockerwith β2-agonism, was compared with that of atenolol, a cardioselective β-blocker, in a 1-year doubl eblindtrial. A total of 143 hypertensive patients (diastolic blood pressure 95-115mmHg after 1 month of placebo) were randomly allocated to either atenolol, 50 mg/day, or indenolol, 60 mg/day. If the target diastolic blood pressure (=S:90mmHg) was not reached after 1 month, the β- blocker was doubled. If the target was still not reached, a diuretic was added after 2 months and doubled after 4 months. There was a higher overall responsiveness and monotherapy was more effective in the atenolol group, but at the lower dose indenolol was more effective than atenolol; however, no differences between drugs were significant. Although the drop-out rate was higher with indenolol, withdrawals due to side effects were similar in both groups. Indenolol was as effective and safe as atenolol in longterm ant ihypertensive therapy.
|Journal||Journal of Hypertension, Supplement|
|Publication status||Published - 1989|
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Internal Medicine